POINT Biopharma Global Inc. (NASDAQ: PNT) stock fell -0.54% on Monday to $7.35 against a previous-day closing price of $7.39. With 0.7 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.63 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $7.58 whereas the lowest price it dropped to was $7.23. The 52-week range on PNT shows that it touched its highest point at $11.13 and its lowest point at $5.59 during that stretch. It currently has a 1-year price target of $16.90. Beta for the stock currently stands at 0.15.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PNT was down-trending over the past week, with a drop of -6.37%, but this was down by -3.54% over a month. Three-month performance dropped to -23.83% while six-month performance fell -1.87%. The stock lost -12.91% in the past year, while it has gained 0.82% so far this year. A look at the trailing 12-month EPS for PNT yields 0.81 with Next year EPS estimates of -0.87. For the next quarter, that number is -0.30. This implies an EPS growth rate of 264.70% for this year and 13.90% for next year.
Float and Shares Shorts:
At present, 105.72 million PNT shares are outstanding with a float of 89.56 million shares on hand for trading. On Aug 30, 2023, short shares totaled 7.04 million, which was 6.66% higher than short shares on Jul 30, 2023. In addition to Mr. Allan Charles Silber as the firm’s Exec. Chairman, Dr. Joe A. McCann Ph.D. serves as its CEO & Director.
Institutional Ownership:
Through their ownership of 59.76% of PNT’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 39.65% of PNT, in contrast to 16.81% held by mutual funds. Shares owned by individuals account for 15.29%. As the largest shareholder in PNT with 9.99% of the stake, BVF Partners LP holds 10,563,748 shares worth 10,563,748. A second-largest stockholder of PNT, BlackRock Fund Advisors, holds 5,649,660 shares, controlling over 5.34% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in PNT, holding 4,336,144 shares or 4.10% stake. With a 2.36% stake in PNT, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 2,497,527 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 1.90% of PNT stock, is the second-largest Mutual Fund holder. It holds 2,006,831 shares valued at 15.97 million. SPDR S&P Biotech ETF holds 1.60% of the stake in PNT, owning 1,689,713 shares worth 13.45 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, PNT reported revenue of $0.00 and operating income of -$24.89M. The EBITDA in the recently reported quarter was -$24.52M and diluted EPS was -$0.27.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PNT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With PNT analysts setting a high price target of $27.00 and a low target of $13.00, the average target price over the next 12 months is $16.90. Based on these targets, PNT could surge 267.35% to reach the target high and rise by 76.87% to reach the target low. Reaching the average price target will result in a growth of 129.93% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded PNT stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 8 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 61,163 while 0 shares were sold.
